JPMorgan analyst Anupam Rama lowered the firm’s price target on Travere Therapeutics to $19 from $23 and keeps an Overweight rating on the shares. The analyst updated models in the SMid cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
- Travere Therapeutics initiated with a Neutral at Citi
- Travere Therapeutics Reports Third Quarter 2023 Financial Results
- TVTX Upcoming Earnings Report: What to Expect?
- Travere Therapeutics to present data from clinical studies of sparsentan
